Clare J Wotton1, Michael J Goldacre. 1. Unit of Health-Care Epidemiology, Department of Public Health, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: Invasive pneumococcal disease is a serious infection, and it is an important cause of morbidity and mortality in certain groups of 'at-risk' people. Those considered 'at-risk' in the UK include very young children, people aged 65 years and older and people with certain serious chronic diseases, asplenia or immunosuppression. There is little evidence about whether people with immune-mediated diseases are at increased risk of pneumococcal disease and therefore may benefit from pneumococcal vaccination. METHODS: Retrospective cohort studies, using linked hospital data, from the longstanding Oxford Record Linkage Study (1963-2008) and from recent English national linked Hospital Episode Statistics (1999-2008); analysis of whether people with immune-mediated diseases are more likely than others to be admitted to hospital for pneumococcal disease; calculation of rate ratio for pneumococcal disease in cohorts with immune-mediated disease compared with control cohorts. RESULTS: There were elevated rate ratios for many of the immune-mediated diseases, for example, Addison's disease in England 3.8 (95% CI 3.4 to 4.2), autoimmune haemolytic anaemia 4.9 (4.4 to 5.3), Crohn's disease 2.2 (2.1 to 2.3), diabetes mellitus 3.7 (3.4 to 4.1), multiple sclerosis 3.7 (3.5 to 3.8), myxoedema 1.60 (1.58 to 1.63), pernicious anaemia 1.74 (1.66 to 1.83), primary biliary cirrhosis 3.3 (2.9 to 3.7), polyarteritis nodosa 5.0 (4.0 to 6.0), rheumatoid arthritis 2.47 (2.41 to 2.52), scleroderma 4.2 (3.8 to 4.7), Sjogren's syndrome 3.2 (2.9 to 3.5) and systemic lupus erythematosus 5.0 (4.6 to 5.4). Findings in the Oxford and all England data sets were similar. CONCLUSIONS: People admitted to hospital with immune-mediated diseases are at higher risk than those with invasive pneumococcal disease. Vaccination should be considered in this group of patients.
BACKGROUND:Invasive pneumococcal disease is a serious infection, and it is an important cause of morbidity and mortality in certain groups of 'at-risk' people. Those considered 'at-risk' in the UK include very young children, people aged 65 years and older and people with certain serious chronic diseases, asplenia or immunosuppression. There is little evidence about whether people with immune-mediated diseases are at increased risk of pneumococcal disease and therefore may benefit from pneumococcal vaccination. METHODS: Retrospective cohort studies, using linked hospital data, from the longstanding Oxford Record Linkage Study (1963-2008) and from recent English national linked Hospital Episode Statistics (1999-2008); analysis of whether people with immune-mediated diseases are more likely than others to be admitted to hospital for pneumococcal disease; calculation of rate ratio for pneumococcal disease in cohorts with immune-mediated disease compared with control cohorts. RESULTS: There were elevated rate ratios for many of the immune-mediated diseases, for example, Addison's disease in England 3.8 (95% CI 3.4 to 4.2), autoimmune haemolytic anaemia 4.9 (4.4 to 5.3), Crohn's disease 2.2 (2.1 to 2.3), diabetes mellitus 3.7 (3.4 to 4.1), multiple sclerosis 3.7 (3.5 to 3.8), myxoedema 1.60 (1.58 to 1.63), pernicious anaemia 1.74 (1.66 to 1.83), primary biliary cirrhosis 3.3 (2.9 to 3.7), polyarteritis nodosa 5.0 (4.0 to 6.0), rheumatoid arthritis 2.47 (2.41 to 2.52), scleroderma 4.2 (3.8 to 4.7), Sjogren's syndrome 3.2 (2.9 to 3.5) and systemic lupus erythematosus 5.0 (4.6 to 5.4). Findings in the Oxford and all England data sets were similar. CONCLUSIONS:People admitted to hospital with immune-mediated diseases are at higher risk than those with invasive pneumococcal disease. Vaccination should be considered in this group of patients.
Authors: Stephen I Pelton; Kimberly M Shea; Raymond A Farkouh; David R Strutton; Sebastian Braun; Christian Jacob; Rogier Klok; Elana S Gruen; Derek Weycker Journal: BMC Infect Dis Date: 2015-10-30 Impact factor: 3.090
Authors: A Steens; D F Vestrheim; I S Aaberge; B S Wiklund; J Storsaeter; M A Riise Bergsaker; K Rønning; E Furuseth Journal: Epidemiol Infect Date: 2014-06-16 Impact factor: 4.434
Authors: Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay Journal: Ann Rheum Dis Date: 2013-10-04 Impact factor: 19.103